Jinye Xie
Jinye Xie has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Fang Wang
Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China
1 shared publication- Guoquan Gao
Department of Biochemistry and Molecular Biology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China
1 shared publication Haofan Yin
Department of Biochemistry, Zhongshan School of Medicine, SunYat-sen University, Guangzhou, 510080, China
1 shared publicationKangyao Sun
Xidian University,College of Communication Engineering,Xian,China
1 shared publication- Liangping Xia
VIP Region, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
1 shared publication - Ti Zhou
Department of Biochemistry and Molecular Biology, Zhongshan School of Medicine Sun Yat‐sen University Guangzhou China
1 shared publication
Latest Publications
- 27 October 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 23, 765-770
Research on the Recognition of Motor Imaging EEG Signals Based on the PSD and the SVM
In the study of brain-computer interface, the EEG signal recognition classification method of motor imaging is one of the hot spots in today's research. In this study, we use frequency domain analysis based on the power spectrum density function to extract features from motor imagery EEG signals for two different motor imagery movements. We then combine with SVM to classify the features because BCI systems currently still have a low recognition rate accuracy. This study finds that employing the power spectrum in conjunction with SVM improves EEG signal classification when compared to alternative classifiers, such as random forest and convolutional neural networks. It can offer algorithmic assistance for the widespread use of BCI systems in everyday life.
- 27 October 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 23, 765-770
Research on the Recognition of Motor Imaging EEG Signals Based on the PSD and the SVM
In the study of brain-computer interface, the EEG signal recognition classification method of motor imaging is one of the hot spots in today's research. In this study, we use frequency domain analysis based on the power spectrum density function to extract features from motor imagery EEG signals for two different motor imagery movements. We then combine with SVM to classify the features because BCI systems currently still have a low recognition rate accuracy. This study finds that employing the power spectrum in conjunction with SVM improves EEG signal classification when compared to alternative classifiers, such as random forest and convolutional neural networks. It can offer algorithmic assistance for the widespread use of BCI systems in everyday life.
- Open Access
- 22 May 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (23) , 13012-13022
Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1
Significance: CRC patients with KRAS mutations are confronted with limited targeted therapeutic options. In this study, we have shown that the median survival time for KRAS -mutation mCRC patients with diabetes on metformin is 37.8 mo longer than those treated with other hypoglycemic drugs in combination with standard systemic therapy. Metformin is preferentially accumulated in KRAS -mutation CRC cells in both primary cell cultures and patient-derived xenografts. The promising therapeutic activity of metformin has a negative correlation with MATE1 expression, which is proven to eliminate metformin from CRC cells. These findings indicate that KRAS -mutation mCRC patients could benefit from metformin treatment, and somatic KRAS status or MATE1 expression should be recommended to predict the therapeutic response of metformin in CRC.
- 22 May 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (23) , 13012-13022
Open AccessMetformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1
Significance: CRC patients with KRAS mutations are confronted with limited targeted therapeutic options. In this study, we have shown that the median survival time for KRAS -mutation mCRC patients with diabetes on metformin is 37.8 mo longer than those treated with other hypoglycemic drugs in combination with standard systemic therapy. Metformin is preferentially accumulated in KRAS -mutation CRC cells in both primary cell cultures and patient-derived xenografts. The promising therapeutic activity of metformin has a negative correlation with MATE1 expression, which is proven to eliminate metformin from CRC cells. These findings indicate that KRAS -mutation mCRC patients could benefit from metformin treatment, and somatic KRAS status or MATE1 expression should be recommended to predict the therapeutic response of metformin in CRC.